The Agreement on trade aspects of intellectual property rights (TRIPS) was negotiated between 1986 and 1994 as part of the Uruguay Round of the General Agreement on Tariffs and Trade (GATT), which led to the creation of the World Trade Organization (WTO). The TRIPS Agreement establishes minimum levels for different types of intellectual property (IP) protection, including copyright, trademarks, patents, industrial design and trade secret protection. Accession to the WTO implies the obligation to respect the TRIPS Agreement. According to the WTO, the agreement attempts to strike a balance between long-term social benefits to society by increasing innovation and short-term costs to society due to lack of access to inventions (World Trade Organization: protection and enforcement). From the WTO Agreement: the Agreements: wto.org/english/thewto_e/whatis_e/tif_e/agrm7_e.htm). A 2003 agreement eased the requirements of the domestic market and allows developing countries to export to other countries where there is a national health problem as long as the exported medicines are not part of a trade or industrial policy.  Drugs exported under such a regime may be packaged or coloured differently to prevent them from harming the markets of industrialized countries. The agreement commonly known by this acronym (1869 U.N.T.S. 299) was one of many agreements reached in Marrakech, Morocco, the TRIPS conditions more imposing standards beyond TRIPS were also discussed.  These free trade agreements contain conditions that limit the ability of governments to create competition for generic drug manufacturers. In particular, the United States has been criticized for promoting protection far beyond the standards prescribed by TRIPS. . .